Record · corpus.blog/posts/01a0875e-1bb1-7222-9d70-4625d5f65188

Why CUE-221 Might Not Beat Omalizumab In CSU And Could Still Separate In Food Allergy

chaotropy.com · published 27 August 2026

A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.

Read the post at chaotropy.com Wayback capture

0blogs citing

First cited: —
Most recent: —
Rank this month: not ranked
External links: 26
Words captured: 2,917

Cited by

No blog we hold has cited this post yet.

Links from this post

Link

Host

https://chaotropy.substack.com/p/why-licensing-a-dual-mechanism-anti

chaotropy.substack.com

https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047d8k.htm

sec.gov

https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-expands-pipeline-exclusive-license-ascendant

cuebiopharma.gcs-web.com

https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-ex99_1.htm

sec.gov

https://www.jacionline.org/article/S0091-6749(22

jacionline.org

https://www.jci.org/articles/view/157765

jci.org

https://www.nature.com/articles/s41467-019-13815-w

nature.com

https://pmc.ncbi.nlm.nih.gov/articles/PMC3875359/

pmc.ncbi.nlm.nih.gov

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.839011/full

frontiersin.org

https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047dex991.htm

sec.gov

https://www.chinadrugtrials.org.cn/

chinadrugtrials.org.cn

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23

thelancet.com

https://onlinelibrary.wiley.com/doi/full/10.1111/cea.12400

onlinelibrary.wiley.com

https://www.nejm.org/doi/full/10.1056/NEJMoa1900408

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1215372

nejm.org

https://onlinelibrary.wiley.com/doi/10.1111/imr.13380

onlinelibrary.wiley.com

https://www.nejm.org/doi/full/10.1056/NEJMoa2312382

nejm.org

https://www.novartis.com/us-en/news/media-releases/new-england-journal-medicine-publishes-phase-iii-data-showing-xolair-omalizumab-significantly-reduced-allergic-reactions-across-multiple-foods-people-food-allergies

novartis.com

https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental

fda.gov

https://onlinelibrary.wiley.com/doi/10.1111/all.70206

onlinelibrary.wiley.com

https://www.allergicliving.com/2024/01/19/novartis-ends-food-allergy-drug-trial-plans-reboot-at-new-dose/

allergicliving.com

https://clinicaltrials.gov/study/NCT04984876

clinicaltrials.gov

https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-rapt-therapeutics/

gsk.com

https://www.globenewswire.com/news-release/2025/10/27/3174511/0/en/RAPT-Therapeutics-Initiates-prestIgE-Phase-2b-Clinical-Trial-of-Ozureprubart-RPT904-in-Patients-with-Food-Allergies.html

globenewswire.com

https://academic.oup.com/jimmunol/article/215/Supplement_1/vkag141.594/8744564

academic.oup.com

https://www.cuebiopharma.com/news/cue-biopharma-announces-appointment-of-james-m-ahlers-as-chief-financial-officer-and-cue-221-investigational-new-drug-submission/

cuebiopharma.com